Introduction
============

Epithelial ovarian cancer (EOC) is the fourth leading cause of female cancer death in the developed world [@B1]. More than 80% of EOC patients have the advanced stage of the disease at the first diagnosis, with 5-year survival rates between 15%-45%, which are extremely low among all types of cancers [@B1]. As a result of the poor prognosis associated with this disease, a number of laboratory tests including CA-125 [@B2], serum albumin [@B3],[@B4], and C-reactive protein [@B5] have been analyzed in an attempt to find an effective diagnostic biomarker.

Hyponatremia is the most common electrolyte abnormality among hospitalized patients, with frequencies varying from 15%-20% for hospitalized patients [@B6] and 47% for cancer patients [@B7]. Although not directly linked with death, hyponatremia has been identified to be associated with increased morbidity and mortality [@B8]. Moreover, it was observed that aggressive management of hyponatremia aided anti-cancer treatment and improves survival [@B9]. Across different types of cancer, the impact of hyponatremia has been most frequently studied for small cell lung cancer due to its well-known underlying cause, namely syndrome of inappropriate antidiuretic hormone (SIADH). In recent years, potential influence of hyponatremia on disease prognosis has also been studied for some other common cancers, such as breast and colorectal cancer [@B10]. To our knowledge, few studies have been performed to examine the prevalence and prognostic value of hyponatremia in EOC. The most recent study performed by Martin and colleagues [@B11] investigated the relationship between preoperative hyponatremia and the prognosis of women with ovarian, fallopian tube, and primary peritoneal cancers using the American College of Surgeons National Surgical Quality Improvement Program database, and observed a prevalence of 10.02% (365/3644) and a positive association between preoperative hyponatremia and lengthening of hospital stays, 30-day postoperative mortality rates, and postoperative complications [@B11]. Nevertheless, whether preoperative hyponatremia may serve as a prognostic marker for EOC progression and long-term survival remains elusive.

To further clarify this issue, we undertook a retrospective cohort study to examine the association between preoperative hyponatremia and progression-free survival (PFS) and overall survival (OS) among EOC patients, using data from a single center hospital.

Materials and Methods
=====================

Study design and patients
-------------------------

The present retrospective cohort study enrolled EOC patients admitted consecutively to Shengjing Hospital of China Medical University between December 1, 2011 and December 31, 2015. The study was approved by the Institutional Review Board of the Ethics Committee of Shengjing Hospital (2015PS38K).

Patients were included if they: 1) were over 15 years of age; 2) had been diagnosed with primary EOC; 3) had undergone a surgical procedure; and 4) had a serum sodium measurement prior to surgery. In contrast, patients were excluded if they: 1) had undergone surgical exploration at other institutions but had received chemotherapy at Shengjing Hospital; 2) had received neoadjuvant therapy/unknown treatment; 3) had not received primary surgery; 4) had a preoperative serum sodium measurement that indicated hypernatremia; 5) had a missing preoperative serum sodium measurement within the 90 days prior to surgery; or 6) had missing information for any of the variables or covariates used in the analyses.

Data collection
---------------

Information on demographic and clinical factors was extracted manually through medical records from the hospital information system of Shengjing Hospital. Clinico-pathological data included the date of diagnosis, tumor histology, tumor grade, International Federation of Gynecology and Obstetrics (FIGO) stage, comorbidity, residual disease, and ascites. Tumor stage was calculated on the basis of the FIGO criteria [@B12]. Tumors were graded as well (G1), moderately (G2), or poorly (G3) differentiated according to the histological typing system of the WHO [@B13]. In addition, residual disease was grouped into "non-detectable", "≤ 1 cm," or "\> 1 cm." Performance status (PS) was assessed in accordance with the criteria of the Eastern Cooperative Oncology Group\'s (ECOG) scale [@B14]. Comorbidity, defined as the presence of one or more diseases in addition to the primary disease, was classified as "yes" or "no" according to the Charlson comorbidity index [@B15]. Histology was classified as \'serous\' and \'non-serous\'. All of the aforementioned data were collected and confirmed by two experienced gynecologists.

Of particular interest in this study was the average serum sodium levels provided by the hospital\'s laboratory center and measured within 90 days prior to surgery. Serum sodium was measured by the electrode method on an Abbott c16200 automatic biochemistry analyzer. We categorized serum sodium levels as normal (136-145 mmol/L) or hyponatremic (≤136 mmol/L).

Outcomes
--------

To evaluate the clinical progression of disease, we manually extracted the data for clinical examinations, serum CA-125 assays, chest x-rays, abdominal-pelvic ultrasounds, and computed tomography scans from the medical records under the criteria of Response Evaluation Criteria in Solid Tumors. The primary endpoint was PFS, defined as the time from the completion of primary surgery to the first progression or recurrence of disease or death from any cause. OS was defined as the time from the completion of primary surgery to death from any cause or the date of last follow-up (December 31, 2017) for patients who were alive. The cause of death was obtained from the death certificates.

Statistical analysis
--------------------

The relationship between preoperative hyponatremia and the demographic and clinico-pathological characteristics of EOC was analyzed using the Mann-Whitney U test for continuous variables and the chi-square test for categorical variables. Continuous variables were summarized as the median with the inter-quartile range (IQR). Categorical variables were expressed as the number with the percentage. The Cox proportional hazards model was applied to calculate hazard ratios (HRs) and 95% confidence intervals (CIs) for the association between preoperative hyponatremia and PFS and OS. We assessed the proportional hazards assumption with a likelihood ratio test.

We conducted multivariable adjusted analyses, including the following potential confounders: age at diagnosis, FIGO stage, histology, residual disease, comorbidity, performance status, ascites, cancer grading, and preoperative serum potassium level. Furthermore, we carried out subgroup analyses stratified by FIGO stage, residual disease, and comorbidity. Likelihood ratio tests were conducted to examine whether the associations between preoperative hyponatremia and PFS and OS were modified by these aforementioned prespecified potential effect modifiers. In sensitivity analyses, we treated the exposure of interest as the most recent serum sodium measured in the 90 days prior to surgery. We also excluded patients who showed recurrence of disease or died within 1 year of study enrollment. All analyses were performed using SAS software, version 9.3 (SAS Institute, Cary, NC, USA).

Results
=======

In total, 1390 women with ovarian, primary peritoneal cancers, and fallopian tube cancers were identified at Shengjing Hospital from December 1, 2011 to December 31, 2015. Of these patients, the following were excluded from the study: 47 women who were diagnosed with primary peritoneal cancers and fallopian tube cancers, 159 patients who had received neoadjuvant chemotherapy, 221 patients who had not undergone primary surgery/underwent surgical exploration at another institution, 14 patients aged younger than 15, 114 patients who had hypernatremia, and 228 patients who had missing information for any of the variables or covariates. Finally, the remaining 607 women with primary EOC and a median age of 51 (IQR: 47-59) were included in the study.

The selected demographic and clinical characteristics of EOC patients according to preoperative serum sodium levels are listed in Table [1](#T1){ref-type="table"}. The median follow-up duration was 3.1 years (IQR: 2.2-4.2), with 345 (56.8%) patients showing disease recurrence and 233 (38.4%) patients dying during this period. The median PFS and OS of all patients were 2.5 years (IQR: 1.2-3.9 years) and 3.1 years (IQR: 2.2-4.2 years), respectively. Over half of the patients were diagnosed without a comorbidity (336 patients, 55.4%). The majority of these cases (458 patients, 75.5%) displayed a bad performance status (PS≥2). A total of 354 (58.3%) patients with EOC were categorized as FIGO stage III/IV. However, interestingly, over one quarter (n=161) of EOC patients were categorized as FIGO stage I. The pathology of the 607 patients consisted of 434 (71.5%) serious EOC cases and 173 (28.5%) non-serious EOC cases. After surgery, 80.2% (487/607) of cases had a residual tumor size of less than 1 cm. In addition, high grade tumors (n=413, 68%) accounted for the majority of tumors in these EOC patients. A total of 81 patients (13.3%) were diagnosed with hyponatremia in this study. However, we failed to detect any significant differences between normal and hyponatremia patients in relation to demographic and clinical characteristics. Table [2](#T2){ref-type="table"} summarizes selected patient characteristics in relation to PFS and OS after mutual adjustment. Possessing a comorbidity, residual disease, and advanced FIGO stage (III/IV) was associated with poorer PFS and OS of EOC patients.

Overall, preoperative hyponatremia showed a 51% reduction in PFS of EOC patients compared with normal patients (HR=1.51, 95% CI=1.07-2.15) after adjustment for potential confounders (Table [3](#T3){ref-type="table"}). Similarly, there was a 47% reduction in OS of EOC patients compared with normal patients (HR=1.47, 95% CI=1.03-2.11) in the multivariable model. Of note, in the subgroup analyses, associations were slightly more marked in FIGO IV patients (for PFS: HR=5.89, 95% CI=1.31-26.54; for OS: HR=3.76, 95% CI=1.04-13.54), in EOC patients with non-detectable residual disease (for PFS: HR=1.74, 95% CI=1.05-2.88), and in patients with \>1 cm residual disease (for PFS: HR=2.17, 95% CI=1.04-4.51). There was no significant interaction effect detected for these variables (P for interaction \>0.05).

In sensitivity analyses, we treated the exposure of interest as the most recent serum sodium measurement taken within the 90 days prior to surgery (Table [4](#T4){ref-type="table"}). These results were similar to the main findings. Furthermore, when we excluded 30 patients who showed recurrent disease within 1 year of study enrollment and 46 patients who died within 1 year of study enrollment, the results were still robust (data not shown).

Discussion
==========

In this retrospective cohort study of 607 EOC patients, we observed a 51% and 47% reduction in the PFS and OS of EOC patients who had preoperative hyponatremia, respectively. These findings were robust in the subgroup and sensitivity analyses.

Hyponatremia has been identified as a negative prognostic factor in several malignancies [@B10],[@B16]. However, recent studies on the prognosis of hyponatremia in EOC are limited. In 2015, Abu and coworkers [@B16] evaluated the potential prognostic value of hyponatremia in EOC by reviewing the medical records of 2,048 patients with more than 20 types of cancers (48 with ovarian cancer) admitted to the National Center for Cancer Care and Research in Qatar between 2008 and 2012.

The severity of hyponatremia was found to be an independent factor predicting significantly higher in-hospital mortality [@B16]. Subsequently, Martin and colleagues [@B11] performed a retrospective population-based cohort study of women with a postoperative diagnosis of ovarian, fallopian tube, or primary peritoneal cancer who had undergone a cytoreductive procedure in the National Surgical Quality Improvement Program database from 2005 to 2013. Unfavorable prognosis of postoperative 30-day mortality and morbidity was observed among patients with hyponatremia compared with patients with normal sodium levels [@B11]. Although we focused on the relatively long-term outcome, the direction of the association was consistent with these published studies.

Previous studies estimated that about 14% of cases of hyponatremia among medical inpatients resulted from underlying tumor-related conditions and the prevalence differed depending on the race, region, and cancer type [@B17]. A study conducted on lymphoma, breast cancer, colorectal cancer, and lung cancer patients observed high prevalence rates of hyponatremia of 60%, 37%, 64%, and 76%, respectively [@B10]. Furthermore, an earlier study on 3,357 cancer patients admitted to the M.D. Anderson Cancer Center during a 3-month period in 2006 identified 47% of these patients as hyponatremic [@B7]. However, notably, the prevalence of EOC in these two studies was completely different. The prevalence of hyponatremia was 58.3% (28/48) in a study by Abu and coworkers [@B16], compared with 10.02% in a study by Martin and colleagues [@B11]. This difference might be partly attributed to the different cut-off values used in the studies. The cut-off value for hyponatremia used in the study by Abu and coworkers [@B16] was 130 mmol/L, while this value was 134 mEq/L for the study by Martin and colleagues [@B11]. It should also be considered that because cancer patients are frequently hyponatremic especially in the advanced stages, EOC has an asymptomatic course and the majority of patients have advanced-stage disease at the time of presentation. Consistent with this, the rates of prevalence of hyponatremia associated with FIGO stages I, II, III, and IV were 10.6%, 15.2%, 13.7%, and 17.1%, respectively, in this study.

Recently, several biological factors have been highlighted that may play a role in the development of hyponatremia in cancer patients. Low appetite, cachexia, and weight loss may induce malnutrition, with reduced sodium levels resulting from decreased oral intake. Furthermore, the high tumor burden, remote metastasis, and leaching of ascites into the peritoneal cavity of advanced malignancies may disturb the sodium balance [@B18] and induce vomiting, diarrhea, and renal fluid and solute losses in cancer patients, giving rise to hypovolemic hyponatremia [@B19]. In addition to malignancies, hyponatremia is seen in various medical conditions such as heart, kidney, and liver failure, as well as following the use of some medications, and the existence of one or more comorbidities increases the risk of hyponatremia [@B20]. Nevertheless, we observed no significant difference between preoperative serum sodium levels and the presence of comorbidities in the present study (Table [1](#T1){ref-type="table"}). Furthermore, it was reported that hyponatremia in cancer patients is usually caused by SIADH, which may be driven by ectopic production of arginine vasopressin (AVP) by tumor tissues or by the effects of anticancer and palliative medications on AVP production or action [@B21]. It was reported that the tumors that were most frequently accompanied by hyponatremia of the SIADH types were lung, breast, and head and neck tumors [@B22].

The present study has several strengths. It was the first, as well as the largest, study exploring the prognostic value of hyponatremia in EOC in Asia, as well as in China. Furthermore, we carried out numerous subgroup analyses stratified by well-established prognostic factors as well as sensitivity analyses to assess whether the main findings were robust. Specifically, we considered not only the preoperative serum sodium levels as average values but also considered the most recent value measured in the 90 days prior to surgery, to check whether a possible correction had occurred and the potential influence of normalization.

This study also had several limitations that should be acknowledged. The first was its retrospective nature, meaning that potential recall and confounding bias might exist. However, in 2014, the Shengjing Hospital of China Medical University became the only "Dual Seven Level" hospital in China reaching level 7 of the Electronic Medical Record System Application Capacity Grading by the Hospital Management Institute of the National Health and Family Planning Commission and level 7 (the highest level) of the Electronic Medical Record Application Evaluation by the American Organization Healthcare Information and Management Systems Society. These achievements indicated the information systems in place in our hospital met the highest national and international standards, thereby minimizing the likelihood of recall bias. Furthermore, we addressed potential confounding bias by adjusting for all relevant covariates through regression models. Second, relatively short follow-up periods (median=3.1 years) and the high number of patients with missing information for variables or covariates (n=288) was a concern in this study. However, although no differences were found between the included and excluded patients in this study, patients excluded due to their lack of serum sodium measurements were more likely to have normal serum sodium levels. Therefore, by including these patients, the results might have been biased towards the null hypothesis. Third, it should be noted that FIGO stage I accounted for a higher proportion of cases (26.5%) compared with other studies. This phenomenon may be attributed to the accidental diagnosis of EOC when checking for other diseases such as benign ovarian tumors as well as myoma. Furthermore, the Department of Obstetrics and Gynecology of China Medical University is the highest authority on EOC diagnosis in northeast China, potentially explaining the early diagnosis of EOC in the present study.

In conclusion, our findings indicated that preoperative hyponatremia was an independent prognostic factor for EOC. Prospective studies are now warranted to confirm these findings. Our study highlighted the importance of early correction of hyponatremia in EOC patients because significantly improved survival was observed in the corrected group compared with other cancer patients [@B23],[@B24]. Therefore, further interventional studies are also needed to investigate this issue in more depth.
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###### 

Selected demographic and clinical characteristics of epithelial ovarian cancer patients according to the average preoperative serum sodium levels measured in the 90 days prior to surgery

  Variables                                     Overall            Normal             Hyponatremia       *P* value ^†^
  --------------------------------------------- ------------------ ------------------ ------------------ ---------------
  **No. of patients**                           607                526                81                 
  **Age at diagnosis (years), Median (IQR)**    51 (47-59)         51 (47-59)         52 (47-59)         0.44
  **Follow-up time (years), Median (IQR)**      3.1 (2.18-4.21)    3.02 (2.18-4.26)   2.91 (2.16-3.80)   0.27
  **Serum potassium (mmol/L), Median (IQR)**    2.54 (1.21-3.88)   4.06 (3.84-4.29)   4.29 (3.86-4.59)   0.15
  **Serum albumin (g/L), Median (IQR)**         41 (36.7-44.1)     41 (36.7-44.1)     41 (37-43.4)       0.83
  **Serum creatinine (μmol/L), Median (IQR)**   54.1 (48.5-60.9)   54 (48.5-61.1)     55.3 (48.1-60.2)   0.93
  **Vital status (%)**                                                                                   0.07
  Alive                                         374 (61.6)         332 (63.1)         42 (51.8)          
  Died                                          233 (38.4)         194 (36.9)         39 (48.2)          
  **Recurrence status (%)**                                                                              0.09
  Yes                                           345 (56.8)         306 (58.2)         39 (48.2)          
  No                                            262 (43.2)         220 (41.8)         42 (51.8)          
  **Comorbidity (%)**                                                                                    0.78
  No                                            336 (55.4)         290 (55.1)         46 (56.8)          
  Yes                                           271 (44.6)         236 (44.9)         35 (43.2)          
  **Performance status (%)**                                                                             0.57
  0                                             4 (0.7)            4 (0.8)            0                  
  1                                             145 (23.9)         125 (23.7)         20 (24.7)          
  2                                             302 (49.8)         265 (50.4)         37 (45.7)          
  ≥ 3                                           156 (25.6)         132 (25.1)         24 (29.6)          
  **FIGO stage (%)**                                                                                     0.59
  I                                             161 (26.5)         144 (27.4)         17 (21)            
  II                                            92 (15.2)          78 (14.8)          14 (17.3)          
  III                                           313 (51.6)         270 (51.3)         43 (53.1)          
  IV                                            41 (6.7)           34 (6.5)           7 (8.6)            
  **Histologic type (%)**                                                                                0.06
  Serous                                        434 (71.5)         369 (70.2)         65 (80.3)          
  Non-serous                                    173 (28.5)         157 (29.8)         16 (19.7)          
  **Residual disease (%)**                                                                               0.81
  None detectable                               373 (61.4)         321 (61)           52 (64.2)          
  ≤ 1 cm                                        114 (18.8)         99 (18.8)          15 (18.5)          
  \> 1 cm                                       120 (19.8)         106 (20.2)         14 (17.3)          
  **Ascites (%)**                                                                                        0.26
  Yes                                           257 (42.3)         218 (41.4)         39 (48.2)          
  No                                            350 (57.7)         308 (58.6)         42 (51.8)          
  **Grading (%)**                                                                                        0.26
  Grade 1                                       31 (5.1)           25 (4.8)           6 (7.4)            
  Grade 2                                       163 (26.9)         137 (26.1)         26 (32.1)          
  Grade 3                                       413 (68)           364 (69.1)         49 (60.5)          

IQR, inter-quartile range.

^†^The Mann-Whitney U and chi-square tests were used for comparing continuous and category variables, respectively.

###### 

Selected demographic and clinical characteristics according to progression-free survival and overall survival among epithelial ovarian cancer patients

  Variables                 PFS       OS                            
  ------------------------- --------- ------------------- --------- -------------------
  **Age at diagnosis**                                              
  ≤ 50                      266/110   1.00 (Ref)          266/96    1.00 (Ref)
  \> 50                     341/152   1.24 (0.96-1.60)    341/137   1.27 (0.97-1.66)
  **Comorbidity**                                                   
  No                        336/132   1.00 (Ref)          336/111   1.00 (Ref)
  Yes                       271/130   1.42 (1.10-1.82)    271/122   1.58 (1.22-2.59)
  **Performance status**                                            
  0-1                       153/62    1.00 (Ref)          153/52    1.00 (Ref)
  2                         302/118   1.00 (0.72-1.38)    302/104   1.19 (0.84-1.68)
  ≥3                        152/82    1.27 (0.88-1.83)    152/77    1.35 (0.92-1.98)
  **FIGO stage (%)**                                                
  I-II                      253/52    1.00 (Ref)          253/45    1.00 (Ref)
  III                       313/176   2.50 (1.75-3.58)    313/153   2.35 (1.62-3.42)
  IV                        41/34     7.05 (4.42-11.24)   41/35     7.77 (4.80-12.57)
  **Histologic type (%)**                                           
  Serous                    434/214   1.00 (Ref)          434/185   1.00 (Ref)
  Non-serous                173/48    0.79 (0.57-1.11)    173/48    0.98 (0.70-1.38)
  **Residual disease**                                              
  None detectable           373/113   1.00 (Ref)          373/91    1.00 (Ref)
  ≤ 1 cm                    114/68    1.72 (1.24-2.39)    114/64    2.19 (1.56-3.09)
  \> 1 cm                   120/81    1.96 (1.42-2.69)    120/78    2.50 (1.79-3.47)
  **Ascites**                                                       
  No                        257/132   1.00 (Ref)          257/123   1.00 (Ref)
  Yes                       350/130   1.06 (0.81-1.39)    350/110   1.24 (0.93-1.65)
  **Grading**                                                       
  Grade 1                   31/10     1.00 (Ref)          31/8      1.00 (Ref)
  Grade 2                   163/59    1.11 (0.57-2.17)    163/50    1.73 (0.82-3.64)
  Grade 3                   413/193   1.42 (0.70-2.87)    413/175   2.02 (0.93-4.39)

CI, confidence interval; FIGO, International Federation of Gynecology and Obstetrics; HR, hazard ratio; OS, overall survival; PFS, progression-free survival.

^†^HRs (95% CIs) for progression-free survival and overall survival were estimated by using multivariable proportional hazard models, mutually adjusted for all other variables listed in the table.

###### 

Hazard ratio (95% CI) for progression-free survival and overall survival among epithelial ovarian cancer patients according to the average preoperative serum sodium levels measured in the 90 days prior to surgery

                         Progression-free survival   Overall survival                                            
  ---------------------- --------------------------- ------------------- ------ ------------ ------------------- ------
  **All patients**       1.00 (Ref)                  1.51 (1.07-2.15)           1.00 (Ref)   1.47 (1.03-2.11)    
  **FIGO stage**                                                         0.07                                    0.06
  I                      1.00 (Ref)                  1.33 (0.27-6.56)           1.00 (Ref)   1.98 (0.39-10.02)   
  II                     1.00 (Ref)                  1.65 (0.67-4.07)           1.00 (Ref)   2.15 (0.81-5.74)    
  III                    1.00 (Ref)                  1.44 (0.92-2.25)           1.00 (Ref)   1.33 (0.83-2.13)    
  IV                     1.00 (Ref)                  5.89 (1.31-26.54)          1.00 (Ref)   3.76 (1.04-13.54)   
  **Residual disease**                                                   0.22                                    0.31
  None detectable        1.00 (Ref)                  1.74 (1.05-2.88)           1.00 (Ref)   1.68 (0.97-2.91)    
  ≤ 1 cm                 1.00 (Ref)                  0.94 (0.45-1.94)           1.00 (Ref)   0.96 (0.47-1.99)    
  \> 1 cm                1.00 (Ref)                  2.17 (1.04-4.51)           1.00 (Ref)   1.87 (0.91-3.84)    
  **Comorbidity**                                                        0.10                                    0.32
  Yes                    1.00 (Ref)                  1.57 (0.94-2.60)           1.00 (Ref)   1.30 (0.77-2.21)    
  No                     1.00 (Ref)                  1.44 (0.88-2.35)           1.00 (Ref)   1.53 (0.92-2.53)    

CI, confidence interval; FIGO, International Federation of Gynecology and Obstetrics; HR, hazard ratio.

^†^HRs (95% CIs) for progression-free survival and overall survival were estimated by using multivariable proportional hazard models that were adjusted for age at diagnosis, FIGO, residual disease, performance status, ascites, grading, and preoperative serum potassium level.

###### 

Hazard ratio (95% CI) for progression-free survival and overall survival among epithelial ovarian cancer patients according to the most recent preoperative serum sodium levels measured in the 90 days prior to surgery

                         Progression-free survival   Overall survival                                            
  ---------------------- --------------------------- ------------------- ------ ------------ ------------------- ------
  **All patients**       1.00 (Ref)                  1.58 (1.12-2.23)           1.00 (Ref)   1.45 (1.02-2.07)    
  **FIGO stage**                                                         0.06                                    0.05
  I                      1.00 (Ref)                  1.24 (0.25-6.09)           1.00 (Ref)   2.30 (0.46-11.38)   
  II                     1.00 (Ref)                  1.94 (0.84-4.50)           1.00 (Ref)   2.42 (1.00-5.84)    
  III                    1.00 (Ref)                  1.19 (0.76-1.86)           1.00 (Ref)   0.97 (0.60-1.55)    
  IV                     1.00 (Ref)                  3.54 (0.90-13.96)          1.00 (Ref)   3.03 (0.87-10.52)   
  **Residual disease**                                                   0.23                                    0.38
  None detectable        1.00 (Ref)                  1.90 (1.17-3.08)           1.00 (Ref)   1.65 (0.97-2.82)    
  ≤ 1 cm                 1.00 (Ref)                  0.94 (0.46-1.95)           1.00 (Ref)   0.96 (0.46-1.97)    
  \> 1 cm                1.00 (Ref)                  2.14 (1.03-4.44)           1.00 (Ref)   1.65 (0.81-3.38)    
  **Comorbidity**                                                        0.07                                    0.32
  Yes                    1.00 (Ref)                  1.77 (1.09-2.89)           1.00 (Ref)   1.33 (0.80-2.22)    
  No                     1.00 (Ref)                  1.43 (0.87-2.34)           1.00 (Ref)   1.52 (0.92-2.52)    

CI, confidence interval; FIGO, International Federation of Gynecology and Obstetrics; HR, hazard ratio.

^†^HRs (95% CIs) for progression-free survival and overall survival were estimated by using multivariable proportional hazard models that were adjusted for age at diagnosis, FIGO, residual disease, performance status, ascites, grading, and preoperative serum potassium level.
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